![\"Headshot](\"\/camed\/files\/2015\/06\/Vipul-Chitalia-1.jpg\")
Now BUSM researchers have developed a promising anti-cancer compound, Factor Quinolinone Inhibitors (FQIs) that specifically impede LSF (a protein involved in many biological processes) DNA-binding, partner protein-binding and transactivation activities. \u201cGiven the critical role of Wnt signaling in CRC tumorigenesis, we set out to examine the effect of FQIs on CRC tumor growth and found we could successfully establish the significant results of LSF inhibition in the suppressed tumor growth,\u201d explains corresponding author Vipul Chitalia, MD, PhD, associate professor of medicine.<\/p>\n
The researchers used several sets of experiments to evaluate the effect of LSF inhibition with FQI-compound in both experimental models and cell culture experiments.\u00a0The goal was to reduce the activity of the Wnt signaling pathway in the models and assess its effect on tumors. The results showed that experimental models who received FQI treatment experienced significantly reduced tumor growth.<\/p>\n
According to the researchers, this illustrates how specifically targeting the pathology of cancer at transcriptional levels profoundly influences successful treatment outcomes. \u201cSuch interplay of cancer pathology needs to be better defined to understand the drivers of heightened risk of tumor growth in CRC patients,\u201d says first author Saran Lotfollahzadeh, MD, Post-doctoral research fellow in BUSM\u2019s renal and vascular section.<\/p>\n